{
    "clinical_study": {
        "@rank": "35275", 
        "arm_group": [
            {
                "arm_group_label": "Blisibimod", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by\n      a composite responder index in subjects who, despite corticosteroid use, continue to have\n      autoantibody positive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by\n      SELENA SLEDAI score \u226510."
        }, 
        "brief_title": "CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis", 
        "condition": "Systemic Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": [
                "Lupus Erythematosus, Systemic", 
                "Nephritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fulfill at least 4 diagnostic criteria for SLE defined by American College of\n             Rheumatology\n\n          -  Positive antinuclear antibodies (ANA) and/or anti-double stranded DNA (anti-dsDNA)\n\n          -  Active SLE disease as defined by SELENA-SLEDAI score \u226510 despite on-going stable\n             corticosteroid therapy\n\n          -  Subjects with stable nephritis may be enrolled\n\n          -  18 years of age or older\n\n        Exclusion Criteria:\n\n          -  Severe active vasculitis, active central nervous system lupus, uncontrolled\n             hypertension or poorly controlled diabetes\n\n          -  Malignancy within past 5 years\n\n          -  Known to be positive for HIV and/or positive at the screening visit for hepatitis B,\n             or hepatitis C\n\n          -  Liver disease\n\n          -  Anemia, neutropenia, or thrombocytopenia\n\n          -  Active infection requiring hospitalization or treatment with parenteral antibiotics\n             within the past 60 days or history of repeated herpetic viral infections\n\n          -  History of active tuberculosis or a history of tuberculosis infection\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074020", 
            "org_study_id": "AN-SLE3332"
        }, 
        "intervention": [
            {
                "arm_group_label": "Blisibimod", 
                "description": "Administered via subcutaneous injection once per week", 
                "intervention_name": "Blisibimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered via subcutaneous injection once per week", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "SLE", 
            "Lupus", 
            "Lupus Erythematosus, Systemic", 
            "Autoimmune Diseases", 
            "A-623", 
            "Blisibimod", 
            "Nephritis"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis", 
        "other_outcome": {
            "measure": "Subgroup analyses of blisibimod effect in subjects with renal manifestations at baseline", 
            "safety_issue": "No", 
            "time_frame": "52 Weeks"
        }, 
        "overall_contact": {
            "email": "mgangal@anthera.com", 
            "last_name": "Monica Gangal", 
            "phone": "510-856-5600"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of responders to the SRI-8 composite responder index", 
            "safety_issue": "No", 
            "time_frame": "52 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to first severe SLE flare", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 52 weeks"
            }, 
            {
                "measure": "Change in the number of actively tender or swollen joints and in mucocutaneous disease activity", 
                "safety_issue": "No", 
                "time_frame": "52 Weeks"
            }, 
            {
                "measure": "Change in proteinuria from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Proportion of subjects able to reduce oral steroid dose", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 52 weeks"
            }, 
            {
                "measure": "Proportion of subjects with improved patient-reported outcomes", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Through week 52"
            }, 
            {
                "measure": "Change from baseline in B cell subsets, anti-dsDNA, C3, C4", 
                "safety_issue": "No", 
                "time_frame": "Through week 52"
            }, 
            {
                "measure": "Safety profile (AEs, vital signs, labs, physical exams)", 
                "safety_issue": "Yes", 
                "time_frame": "Through week 52"
            }
        ], 
        "source": "Anthera Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anthera Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}